Last reviewed · How we verify
routine dual antiplatelet
At a glance
| Generic name | routine dual antiplatelet |
|---|---|
| Sponsor | Shenyang Northern Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction (PHASE4)
- Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
- Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair (PHASE2, PHASE3)
- Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
- Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery (NA)
- Endovascular Acute Stroke Intervention - Tandem OCclusion Trial (NA)
- The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- routine dual antiplatelet CI brief — competitive landscape report
- routine dual antiplatelet updates RSS · CI watch RSS
- Shenyang Northern Hospital portfolio CI